FULCRUM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.64 USD | -0.78% |
|
-3.41% | +13.19% |
Presenter SpeechJudah Frommer (Analysts)All right. Welcome, everyone, to this session of the C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Companyâs clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
Calendar
2024-06-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.64
USD
Average target price
15.22
USD
Spread / Average Target
+99.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.19% | 475M | |
| +44.48% | 55.07B | |
| +43.85% | 40.22B | |
| -0.86% | 41.79B | |
| -7.59% | 28.17B | |
| +12.30% | 26.28B | |
| -21.83% | 18.93B | |
| +7.15% | 13.03B | |
| +29.40% | 12.26B | |
| +25.15% | 12.21B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Transcript : Fulcrum Therapeutics, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-08-2022 02
